Intra-Cellular Therapies Inc (NASDAQ: ITCI) kicked off on Tuesday, down -0.09% from the previous trading day, before settling in for the closing price of $76.82. Over the past 52 weeks, ITCI has traded in a range of $45.50-$84.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 7617.73% over the past five years. While this was happening, its average annual earnings per share was recorded 58.75%. With a float of $98.77 million, this company’s outstanding shares have now reached $105.67 million.
Let’s look at the performance matrix of the company that is accounted for 610 employees. In terms of profitability, gross margin is 92.71%, operating margin of -19.96%, and the pretax margin is -14.8%.
Intra-Cellular Therapies Inc (ITCI) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Intra-Cellular Therapies Inc is 6.53%, while institutional ownership is 91.83%. The most recent insider transaction that took place on Sep 06 ’24, was worth 1,829,178. Before that another transaction happened on Aug 29 ’24, when Company’s Chairman and CEO sold 35,604 for $72.57, making the entire transaction worth $2,583,884. This insider now owns 1,070,329 shares in total.
Intra-Cellular Therapies Inc (ITCI) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 58.75% per share during the next fiscal year.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Trading Performance Indicators
Take a look at Intra-Cellular Therapies Inc’s (ITCI) current performance indicators. Last quarter, stock had a quick ratio of 7.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach 0.69 in one year’s time.
Technical Analysis of Intra-Cellular Therapies Inc (ITCI)
Intra-Cellular Therapies Inc (NASDAQ: ITCI) saw its 5-day average volume 0.45 million, a negative change from its year-to-date volume of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 41.18%. Additionally, its Average True Range was 1.88.
During the past 100 days, Intra-Cellular Therapies Inc’s (ITCI) raw stochastic average was set at 66.65%, which indicates a significant increase from 63.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.75% in the past 14 days, which was lower than the 30.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $74.61, while its 200-day Moving Average is $71.61. Nevertheless, the first resistance level for the watch stands at $77.99 in the near term. At $79.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $80.44. If the price goes on to break the first support level at $75.54, it is likely to go to the next support level at $74.33. The third support level lies at $73.09 if the price breaches the second support level.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Key Stats
The company with the Market Capitalisation of 8.11 billion has total of 105,667K Shares Outstanding. Its annual sales at the moment are 464,370 K in contrast with the sum of -139,670 K annual income. Company’s last quarter sales were recorded 161,390 K and last quarter income was -16,220 K.
